Bone scintigraphy can also be used to follow tumor response to therapy.

No relationship between Catrix dose and tumor response could be established in this study.

One patient received radiation therapy before entering the study, so tumor response cannot be attributed solely to A3.

One patient had complete tumor response, and there were two partial responses.

Only patients with measurable disease at baseline should be included in protocols where objective tumor response is the primary endpoint.

It is also used in the context of studying the genomics of tumor response to radiation therapy.

The endpoint of the study was objective tumor response.

A number of studies have demonstrated that certain chemotherapy drugs can induce tumor responses as single agents or in combination.

If no patient had experienced an objective tumor response, the study would have been terminated.

Only 20 of the 24 clinical trial patients (83%) were evaluated for tumor responses.